Posts Tagged ‘GLP-1 agonists’

Trends for metabolic and bariatric surgery are still wobbly as GLP-1 utilization continues to grow. This much is quite clear from a new research letter in JAMA Surgery. What is less clear is any consensus on where the trends will go as health systems and people living with obesity confront the reality of obesity as […]

Neglect is a strong word. But if we want to be honest about the excessive emphasis on weight loss in obesity care, it seems appropriate. Research on new therapies for obesity have long neglected the challenge of maintenance therapy for this chronic disease. A new study in Obesity makes this gap plain to see. A […]

Many surprising twists await us in the interaction between food marketing and the rise of GLP-1 medicines for treating obesity. Eating habits are changing for the people who take them. In part, this is happening because of a reduction in food noise – intrusive, persistent, and unpleasant thoughts about food. But the effects of this […]

For better or worse – and maybe a bit of both – body positivity is in the midst of change. People are ascribing it to the availability and uptake of GLP-1s for treating obesity. In a video essay for the New York Times, Gabriella Lascano explains the journey she has taken to become a former […]

When people take a GLP-1 like semaglutide, osteoarthritis often improves. It makes sense. Excess body weight puts a strain on joints, especially the knee. And randomized controlled studies document the clinical benefits. New research confirms what clinical scientists have long suspected. Treating obesity can do more than just relieve the strain of excess weight on […]

Good luck if you want to make sense of headlines about health insurance and coverage trends for GLP-1 medicines. Peruse the headlines and you can find just about any narrative you want. “Rising health premiums push more small business to drop coverage,” according to Inc. “Employers are opting out of covering GLP-1s,” claims Hines, a […]

We are in the midst of what used to be known as diet and weight loss season. And now the Super Bowl is coming up. Instead of diet ads this year, our video feeds are full of ads for telehealth and GLP-1s. Some of them are annoying. But when Serena Williams comes on screen to […]

It is taking a long time for diet culture to fade into oblivion. But we are well down that road when celebrity culture meets obesity science in a new book by Oprah Winfrey and Ania Jastreboff. It’s remarkable, really, that we have come to a time when one of the most iconic persons in the […]

A big change is afoot and the hype is cranking up. With the launch of Wegovy tablets by Novo Nordisk yesterday, we are seeing some very big expectations expressed for a new era in obesity care. The stock market has boosted the value of Novo stock by 15 percent since FDA approved these tablets. Yesterday […]

We do not feel any nostalgia for “diet season.” None. Its demise was apparent two years ago. But in its place, it seems we have a telehealth GLP-1 season. Rebel Wilson is screaming at us to sign up for microdosing with a GLP-1. Put those ads together with somewhat calmer advertising from Ro and Hims, […]